Corvus Pharmaceuticals (NASDAQ: CRVS) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, earnings, dividends, valuation and profitability.
Risk and Volatility
Corvus Pharmaceuticals has a beta of -1.5, suggesting that its share price is 250% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 2.05, suggesting that its share price is 105% more volatile than the S&P 500.
Insider & Institutional Ownership
82.7% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.5% of Achieve Life Sciences shares are owned by institutional investors. 46.4% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 35.8% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Corvus Pharmaceuticals and Achieve Life Sciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Achieve Life Sciences||0||0||0||0||N/A|
Corvus Pharmaceuticals currently has a consensus price target of $21.67, suggesting a potential upside of 109.95%. Given Corvus Pharmaceuticals’ higher probable upside, equities research analysts clearly believe Corvus Pharmaceuticals is more favorable than Achieve Life Sciences.
This table compares Corvus Pharmaceuticals and Achieve Life Sciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Achieve Life Sciences||N/A||-138.65%||-118.38%|
Earnings and Valuation
This table compares Corvus Pharmaceuticals and Achieve Life Sciences’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Corvus Pharmaceuticals||N/A||N/A||-$55.66 million||($2.72)||-3.79|
|Achieve Life Sciences||$5.06 million||3.50||-$10.58 million||($3.53)||-0.39|
Achieve Life Sciences has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.
Corvus Pharmaceuticals beats Achieve Life Sciences on 7 of the 11 factors compared between the two stocks.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company’s lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
About Achieve Life Sciences
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.